Solvonis Therapeutics receives US patent allowance for ketamine addiction treatment

Solvonis Therapeutics says the US Patent and Trademark Office has allowed its method-of-use patent application covering treatment of all behavioral addictions using ketamine at dissociative doses of at least 50 mg, which the company calls a major milestone establishing a broad US patent position.

Detected & updated continuously · Source: Nebula